Type:Notice
Citation:90 FR 3173
Reading Time:about a minute or two
Merck, Sharp & Dohme LLC has informed the Foreign-Trade Zones (FTZ) Board about proposed production activities at their Rahway, New Jersey, facility, which is part of Subzone 49Y. The proposal includes producing drugs for metabolic and immunological disorders using specific foreign-sourced materials. Interested parties can submit their comments to the FTZ Board by February 24, 2025. More details and the notification can be accessed on the Board's website.
Simple Explanation
Merck, Sharp & Dohme wants to make new medicines for certain illnesses in their New Jersey factory using some materials from other countries, and the government is asking anyone who is interested to tell them what they think about this plan by February 24, 2025.